Navigation Links
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Date:11/27/2007

MOUNTAIN VIEW, Calif., Nov. 27 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following upcoming investor conferences on November 28th and December 12th, 2007 in New York City:

Lazard Capital Markets Fourth Annual Healthcare Conference

Wednesday, November 28, 2007

2:30 pm, Eastern Time

RBC Capital Markets 2007 Healthcare Conference

Wednesday, December 12, 2007

12:30 pm, Eastern Time

A live webcast of the presentations will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including its two most advanced product candidates, a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine, as well as a proprietary combination of an inhaled corticosteroid and a long-acting beta2-agonist for the potential treatment of asthma and chronic obstructive pulmonary disease. Additional information about MAP Pharmaceuticals can be found at

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...stained Energy Enhancing Supplement, BOCA RATON, ...sed,nutritional supplement manufacturer, introduce...., Glyc,n Go, is the first and only chewable form...t, and the effects that it has on the,energy syste...trainers,around the globe., In clinical trials, t...
(Date:10/13/2008)...wswire/ -- NeoVista, Inc., presented,yesterday the...l,brachytherapy device on choroidal neovascular le...tina Specialist,s (ASRS) 26th Annual Meeting. The,...S., of The Methodist,Hospital, Houston, Texas, dem...y and ocular coherence tomography (OCT) in many pa...
(Date:10/13/2008)...taJobs.com and numerous newspaper affiliates have ...com . AtlantaJobs.com is the newest online job bo...bseekers in the metro Atlanta area. , ...-- AtlantaJobs.com and numerous newspaper affili...aJobs.com is the newest online job board dedicate...
(Date:10/12/2008)... Five neonatology fellows have been awarded grants...e area of follow-up care of the premature infant a...ts, which underscore MedImmune,s commitment to exp...ovide each recipient,s institution a $35,000 grant...recipients were acknowledged on Sunday, October 12...
Breaking Medicine News(10 mins):Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
...ts. Now, BT Offices and Vans will sport an anti-sm...ng is banned in the BT premises as well as in the ...tantly, this move might encourage “anti-smoking” i...n. The anti-smoking activists have seconded this ...
... improvement with Viagra could now benefit from st...ighlight the use of statins for management of endo...m erectile dysfunction. The result of this small, ...ennsylvania researchers is published in the Journa...
... Railways to take off chicken and egg related dish...n issued to all the Zonal Railways and other railw...fficial quoted that such a decision was taken upon...rest. As the disease itself is highly contagious,...
...construct a world-class cancer hospital and resear...come up at Rajarhat,// at the cost of Rs. 1.2 bill... Centre (TMC) would come up on a 10-acre plot, Wes...tacharjee and Tata Group chairman Ratan Tata said,...
Other Medicine News:Health News:Statins For Erectile Dysfunction- An Alternative To Viagra? 2
(Date:10/12/2008)...and WASHINGTON, Oct. 12 /- ...announced results from an analysis,of nearly 7,500..., which,are designed to confirm the performance of...nary Stent System in real-world practice. The,two-...t reduced clinical,restenosis in patients with dia...
(Date:10/10/2008)...Mich., Oct. 10 /- Diplomat Specialty,...s selected Diplomat,Specialty Pharmacy to be one o..., national Therapy Optimization Study for Multiple...OP MS study, is to examine the benefits of a,speci...ance, adherence and,patient outcomes. Targeted pat...
(Date:10/10/2008)..., Oct. 10 /- Inverness Medi...vider of near-patient,diagnostics, monitoring and ...n Ki-moon, the Secretary-General of the United Nat...eventeen of the world,s leading,research-based and...Inverness, together with senior officials from the...
(Date:10/10/2008)...lif., Oct. 10 /- TriReme Medical Inc.... to affix the CE (Conformite,Europeenne) marking a...y,Stent System, a unique main vessel stent system ...urcations., Representing the next generation in b...tential use in a quarter of the 2.2 million,angiop...
Breaking Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 1Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 1Nventa updates progress of cervical dysplasia trial with new HspE7 1339 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 3Nventa updates progress of cervical dysplasia trial with new HspE7 1339 4Nventa updates progress of cervical dysplasia trial with new HspE7 1339 5Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 1FDA Panel Mulls Ban on Kids Cold Medicines 4019 2FDA Panel Mulls Ban on Kids Cold Medicines 4019 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 4
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: